IPP Bureau
Granules India receives ANDA approval for Levetiracetam Tablets
By IPP Bureau - June 15, 2023
Granules now has a total of 58 ANDA approvals from US FDA
Baghel inaugurates the World Blood Donor Day at RML Hospital
By IPP Bureau - June 15, 2023
The slogan for this year's World Blood Donor Day campaign is 'Give blood, give plasma, share life, share often'
Euroapi plans initiatives to support production of APIs in France and Europe
By IPP Bureau - June 15, 2023
Total investments could reach €70 million, of which approximately 15% in R&D and 85% in capex, that would be deployed from 2026
Zydus receives final approval from the USFDA for Diclofenac Sodium and Misoprostol Delayed Release Tablets
By IPP Bureau - June 14, 2023
Diclofenac Sodium and Misoprostol Delayed Release Tablets USP, 50mg/200 mcg and 75mg/200 mcg had annual sales of USD 13 mn in the United States
Granules India received ANDA approval for Metoprolol Succinate ER Tablets
By IPP Bureau - June 14, 2023
Metoprolol Succinate ER Tablets are indicated for the treatment of hypertension in order to lower blood pressure.
.jpeg "Ampath expands its footprint in Andhra Pradesh")
Ampath expands its footprint in Andhra Pradesh
By IPP Bureau - June 14, 2023
Launched Pathology Laboratory in Vijayawada offering a wide range of best-in-class diagnostic services with over 2500+ tests
Samsung Biologics and Pfizer collaborate for long-term manufacturing of biosimilars portfolio
By IPP Bureau - June 14, 2023
Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product biosimilars portfolio
Merck gets favourable verdict in patent infringement lawsuit related to Bridion
By IPP Bureau - June 14, 2023
Patent Term Extension is designed to restore some of the patent life lost during the regulatory review process for new drugs.
Pfizer and GSK to battle for share of new RSV vaccine market, says GlobalData
By IPP Bureau - June 13, 2023
Pfizer is likely to show GSK significant competition
InnoCan submits new patent applications for advanced pain relief technology
By IPP Bureau - June 13, 2023
The application is in line with Innocan's strategy to expand the scope of its combined magnesium and cannabis topical solution
Croma-Pharma enrolls first patient in hyaluronic acid dermal filler clinical trial in China
By IPP Bureau - June 13, 2023
The randomised, multi-centre, evaluator blinded, parallel group, active controlled Phase 3 trial is being led by Lanhzou Biotechnique Development
Biostar announces first patient enrolled for Phase 1 study of Utidelone Capsule
By IPP Bureau - June 13, 2023
UTD2 is the world's first oral epothilone microtubule inhibitor
Astellas submits new drug application for Zolbetuximab in Japan
By IPP Bureau - June 13, 2023
Ministry of Health, Labour and Welfare to evaluate zolbetuximab as treatment option for patients with advanced gastric and gastroesophageal cancers
Solvay to build a multipurpose microbiology lab in Europe
By IPP Bureau - June 13, 2023
The new lab will enable the Group to accelerate its efforts in this area, building new competencies and capabilities, as well as strengthening Solvay’s ability to develop breakthroughs in biodegradable-by-design solutions.
GSK receives USFDA file acceptance for Jemperli plus chemotherapy for the treatment of endometrial cancer
By IPP Bureau - June 12, 2023
Application being reviewed under the FDA Project Orbis framework, which enables concurrent reviews among US, Australia, Canada, Switzerland, Singapore and United Kingdom health authorities
